# A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab

> **NCT06241573** · PHASE2,PHASE3 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 39 (actual)

## Conditions studied

- Hidradenitis Suppurativa (HS)

## Interventions

- **DRUG:** Spesolimab

## Key facts

- **NCT ID:** NCT06241573
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-05-08
- **Primary completion:** 2025-04-11
- **Final completion:** 2025-04-11
- **Target enrollment:** 39 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2026-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06241573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06241573, "A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06241573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*